ERBB2 and non-small cell lung carcinoma: The DESTINY-Lung01 phase 2 study reported ORRs of 26–34% in heavily pretreated HER2-positive tumors, establishing T-DXd as the first available therapy for HER2-mutant NSCLC [121].